The Effects of VEGF-B Signaling Pathway in Obesity and Metabolic Disease

NCT ID: NCT03164005

Last Updated: 2021-04-08

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 194 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2017-04-20
• Study Completion Date: 2018-03-01

Brief Summary

The investigators will enroll about 120 subjects from the hospital's healthcare center. The investigators will collect the basic informations, blood pressure, body mass index, fasting blood glucose and fasting blood lipids of each subject. The investigators will collect the blood samples and then test them for fasting insulin levels, VEGF-B levels, the gene promoter region methylation status and the genomic protein methylation levels of the VEGF-B gene of the cells，and finally do the statistical analysis.

Detailed Description

The investigators will enroll about 120 subjects from the hospital's healthcare center, and these 120 subjects will be divided into four groups: normal weight with or without metabolic diseases and obesity with or without metabolic diseases. Each group has 30 subjects. The investigators will collect the basic information(name, gender，age, medical history，family history, etc.), blood pressure, body mass index, fasting blood glucose and fasting blood lipids of each subject from the healthcare center. The investigators will collect the blood samples of each subject,separate the plasma and then test the fasting insulin, VEGF-B levels by ELISA. The investigators will separate the peripheral blood mononuclear cells from the blood, and then test the gene promoter region methylation status of the VEGF -B gene by PCR and the bisulfite-modified sequencing and test the genomic protein methylation level of the VEGF-B gene by chromatin immunoprecipitation assay(CHIP) and real-time quantitative PCR of the cells，and finally do the statistical analysis.

Conditions

Obesity; Metabolic Disease

Study Design

• Observational Model Type: CASE_ONLY
• Study Time Perspective: CROSS_SECTIONAL

Study Groups

Group 1

subjects without metabolic diseases

No interventions assigned to this group

Group 2

subjects with metabolic diseases

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

• NA

Exclusion Criteria

• subjects with active history insulin treatment; and female participant pregnant at the time of recruitment.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

OTHER

Sponsor Role: lead

Responsible Party

Chen Lulu

Head of Endocrinology

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Chen Lulu

Role: PRINCIPAL_INVESTIGATOR

Department of Endocrinology, Union Hospital,Tongji Medical College, Huazhong University of Science and Technology

Locations

Department of Endocrinology, Union Hospital,Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, China

Countries

China

Other Identifiers

2016CFA025

Identifier Type: -

Identifier Source: org_study_id